VALN — Valneva SE

Valneva Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenues: Exceeded EUR 170 million, slightly above 2024 levels.
• Product Sales: Approximately EUR 160 million, with a decrease of 3.3% year-over-year (1.3% at constant currency).
• IXIARO Sales: EUR 98.4 million, up 4.6% from 2024.
• DUKORAL Sales: Essentially flat at EUR 31.9 million.
• IXCHIQ Sales: Increased to EUR 8.4 million from EUR 3.7 million in the prior year.
• Operating Loss: EUR 82.1 million, compared to an operating profit of EUR 13.3 million in 2024, largely due to the absence of nonrecurring income from the sale of a priority review voucher.
• Net Loss: EUR 115.2 million.
• Adjusted EBITDA: Reported at minus EUR 51.4 million.
• Cash Position: Nearly EUR 110 million at year-end, with a 20% reduction in operating cash burn.

2. Strategic Updates and Business Highlights

• Lyme Disease Vaccine (VLA15): Advanced in Phase III trials with Pfizer; expected data release in H1 2026. This vaccine addresses a significant unmet medical need, with no current vaccine available for Lyme disease.
• IXCHIQ (Chikungunya Vaccine): Ongoing pilot vaccination campaign in Brazil, with promising uptake. Focus on post-marketing effectiveness studies and expanding access in endemic countries.
• Shigella Vaccine (S4V2): Two Phase II studies underway, with data expected mid-2026. Positioned as a first-in-class vaccine for a high-need area.
• R&D Focus: Plans to expand beyond vector-borne diseases and enhance the pipeline through potential in-licensing opportunities.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected total product sales of EUR 145 million to EUR 160 million, total revenues of EUR 155 million to EUR 170 million. The decrease is attributed to further planned reductions in third-party product sales.
• Long-term Goals: Positive results from the Lyme vaccine could lead to financial self-sustainability and profitability, with a focus on enhancing the R&D pipeline.

4. Bad News, Challenges, or Points of Concern

• Operating Loss: Significant shift from profit to loss, primarily due to the absence of prior nonrecurring income.
• Sales Decline: Overall product sales decreased, particularly in third-party sales due to planned terminations of distribution contracts.
• Manufacturing Issues: DUKORAL faced batch failures affecting gross margins, and IXCHIQ incurred inventory write-offs due to contract terminations.
• Market Conditions: Geopolitical uncertainty and rising vaccine hesitancy pose ongoing challenges for the biotech sector.

5. Notable Q&A Insights

• Lyme Vaccine Data Timing: Pfizer controls the Phase III study; Valneva is hopeful for data release in mid-H1 2026 but cannot confirm specifics.
• Capital Allocation Post-Lyme Success: No immediate financial changes expected post-Phase III results; focus will remain on pipeline development.
• Shigella Program Development: The outcome of the Phase II studies will inform future development decisions, with pilot efficacy data being crucial.
• DoD Contract: Anticipation of a new contract for IXIARO, which is included in the 2026 revenue guidance, although timing remains uncertain.

Overall, Valneva is navigating a complex landscape with promising vaccine candidates while managing financial challenges and operational risks. The upcoming data on the Lyme vaccine is seen as a pivotal moment for the company.